Societal cost of oropharyngeal cancer by human papillomavirus status, cancer stage, and subsite

• DOI: 10.1371/journal.pone.0220534
• Publication Date: 2019-07-29T17:39:26Z
• Authors: Maria Silfverschiöld; Johanna Sjövall; Johan Wennerberg; Ellinor Östensson; Lennart Greiff
• Keywords: Papillomaviridae

Background The incidence of oropharyngeal cancer (OPC) is increasing, particularly human papillomavirus (HPV)-associated OPC. aim this study was to specify the total societal cost OPC by HPV status, stage, and subsite using a bottom-up cost-of-illness approach. Methods We analyzed 121 consecutive patients with from Southern Health Care Region Sweden. estimated direct medical costs indirect (e.g., disease-related morbidity premature death) 1 month prior diagnosis until 3 years after treatment completion. Results mean per patient €103 386 for HPV-positive €120 244 HPV-negative Eighty-one percent were HPV-positive: Accordingly, represented 79% stage I, II, III, IVA, IVB, IVC, regardless €59 424, €57 000, €69 246, €115 770, €234 459, €21 930, respectively, which at €22 493 (37.8%), €14 754 (25.9%), €28 681 (41.4%), €67 107 (58%), €166 280 (70.9%), €0. Tonsillar 64% OPC, €117 512 patient. Conclusion substantial. HPV-associated comprises disease. data presented in may be used analytical models aid decision makers determining potential value gender-neutral vaccination.